One place. Endless possibilities.
|
Pink Sheets: STOA Stock Quote
Pink Sheets: STOA Overview
Sinobiomed Inc. is engaged in research, development and commercialization activities in China's biopharmaceutical industry. The initial business plan of the Company was to develop United States patent No. 5,074,073 (the Patent) for a Car Door Safety Feature Device, which it owns. Sinobiomed, however, determined to change its business plan from the development of the Patent and began focusing on the Chinese biopharmaceutical market. In January 2007, the Company completed a share purchase agreement entered into with Wanxin Bio-Technology Limited (Wanxin), whereby Sinobiomed acquired 100% of Wanxin. In January 2011, the Company sold its wholly owned BVI subsidiary, Wanxin Bio-Technology Limited (Wanxin) and its Chinese subsidiaries, Shanghai Wanxin Bio-Pharmaceutical Co Ltd. and Shanghai Bio-Science Cosmetic Co Ltd.
|
|
|||||||||||||||||||||||||||||||||||||||||
Do you know of another great research resource for STOA that belongs here? Please let us know and provide the URL.